Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Akari Therapeutics, Plc before investing.

In this article, we go over a few key elements for understanding Akari Therapeutics, Plc’s stock price such as:

• Akari Therapeutics, Plc’s current stock price and volume
• Why Akari Therapeutics, Plc’s stock price changed recently
• Upgrades and downgrades for AKTX from analysts
• AKTX’s stock price momentum as measured by its relative strength

About Akari Therapeutics, Plc (AKTX)

Before we jump into Akari Therapeutics, Plc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Want to learn more about Akari Therapeutics, Plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Akari Therapeutics, Plc.

Akari Therapeutics, Plc’s Stock Price as of Market Close

As of July 31, 2026, 11:37 AM, CST, Akari Therapeutics, Plc’s stock price was $7.800.

Akari Therapeutics, Plc is down 2.5% from its previous closing price of $8.000.

During the last market session, Akari Therapeutics, Plc’s stock traded between $7.800 and $8.100. Currently, there are approximately 1.48 million shares outstanding for Akari Therapeutics, Plc.

Akari Therapeutics, Plc’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Akari Therapeutics, Plc Stock Price History

Akari Therapeutics, Plc’s (AKTX) price is currently down 23.87% so far this month.

During the month of July, Akari Therapeutics, Plc’s stock price has reached a high of $15.500 and a low of $7.720.

Over the last year, Akari Therapeutics, Plc has hit prices as high as $49.600 and as low as $3.015. Year to date, Akari Therapeutics, Plc’s stock is down 32.53%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Akari Therapeutics, Plc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 0 analysts who downgraded Akari Therapeutics, Plc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Akari Therapeutics, Plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Akari Therapeutics, Plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Akari Therapeutics, Plc (AKTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Akari Therapeutics, Plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Akari Therapeutics, Plc has a weighted four-quarter relative price strength of -11.30%, which translates to a Momentum Score of 21 and is considered to be Weak.

Want to learn more about how Akari Therapeutics, Plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Akari Therapeutics, Plc Stock Price: Bottom Line

As of July 31, 2026, Akari Therapeutics, Plc’s stock price is $7.800, which is down 2.5% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Akari Therapeutics, Plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.